Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook.
Back to Business
Business
November 16, 2026 at 5:00 AM
Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback
SCMP Business
Excerpt from SCMP Business.